Table 3.
Most common (frequency ≥ 20%) treatment-related adverse events categorized by highest grade experienced per patient (N = 19)
| All Grades | Grade 1 | Grade 2 | Grade 3a | Grade 4 | |
|---|---|---|---|---|---|
| Non-Hematological | |||||
| Elevated AST | 15 (79%) | 10 | 2 | 3 | 0 |
| Fatigue | 15 (79%) | 2 | 11 | 2 | 0 |
| Nausea | 14 (74%) | 8 | 5 | 2 | 0 |
| Elevated ALT | 14 (74%) | 10 | 2 | 2 | 0 |
| Diarrhea | 11 (58%) | 9 | 2 | 0 | 0 |
| Dysgeusia | 9 (47%) | 3 | 6 | 0 | 0 |
| Rash | 9 (47%) | 9 | 0 | 0 | 0 |
| Anorexia | 8 (42%) | 2 | 6 | 0 | 0 |
| Oral Mucositis | 7 (37%) | 5 | 1 | 1 | 0 |
| Vomiting | 6 (32%) | 3 | 1 | 2 | 0 |
| Peripheral Edema | 6 (32%) | 3 | 3 | 0 | 0 |
| Elevated Alkaline Phosphatase | 5 (26%) | 3 | 2 | 0 | 0 |
| Fever | 4 (21%) | 4 | 0 | 0 | 0 |
| Hematological | |||||
| Anemia | 17 (89%) | 3 | 11 | 3 | 0 |
| Lymphocytopenia | 14 (74%) | 2 | 6 | 5 | 1 |
| Leukopenia | 14 (74%) | 2 | 8 | 4 | 0 |
| Neutropenia | 12 (63%) | 0 | 3 | 6 | 3 |
| Thrombocytopenia | 12 (63%) | 7 | 3 | 2 | 0 |
| Hypophosphatemia | 11 (58%) | 1 | 10 | 0 | 0 |
AST: aspartate aminotransferase; ALT: alanine aminotransferase
a
Additional Grade 3 dyspnea observed by one patient